Bionano Genomics, Inc.
BNGO
$4.08
-$0.02-0.49%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.82% | 16.08% | 26.93% | 29.90% | 29.82% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.82% | 16.08% | 26.93% | 29.90% | 29.82% |
| Cost of Revenue | 37.50% | 10.47% | 21.39% | 21.48% | 14.73% |
| Gross Profit | -106.71% | 32.58% | 44.22% | 60.86% | 103.93% |
| SG&A Expenses | -39.85% | -21.62% | -0.42% | 11.51% | 23.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.81% | -18.03% | 1.09% | 12.47% | 23.22% |
| Operating Income | 36.39% | 25.49% | 4.48% | -8.74% | -21.82% |
| Income Before Tax | 39.75% | -41.11% | -64.49% | -77.82% | -83.89% |
| Income Tax Expenses | -100.21% | -99.42% | -99.05% | -96.71% | 133.45% |
| Earnings from Continuing Operations | 40.26% | -39.30% | -62.26% | -75.34% | -94.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.26% | -39.30% | -62.26% | -75.34% | -94.47% |
| EBIT | 36.39% | 25.49% | 4.48% | -8.74% | -21.82% |
| EBITDA | 41.61% | 28.93% | 7.13% | -6.04% | -20.00% |
| EPS Basic | 64.88% | -5.92% | -29.28% | -48.10% | -70.95% |
| Normalized Basic EPS | 51.03% | 36.25% | 13.99% | -4.42% | -9.19% |
| EPS Diluted | 64.80% | -6.02% | -29.38% | -48.16% | -70.98% |
| Normalized Diluted EPS | 51.03% | 36.25% | 13.99% | -4.42% | -9.19% |
| Average Basic Shares Outstanding | 94.66% | 62.16% | 35.50% | 18.05% | 10.51% |
| Average Diluted Shares Outstanding | 94.66% | 62.16% | 35.50% | 18.05% | 10.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
